Filing Analysis
Entrada Therapeutics, Inc. announced its financial results for the quarter ended June 30, 2026, and provided other corporate updates via a press release.
📋 Key Facts
- Reporting period: Quarter ended June 30, 2026
- Announcement date: August 5, 2026
- The filing includes results of operations and financial condition under Item 2.02.
Entrada Therapeutics, Inc. filed an 8-K to furnish its quarterly financial results for the period ending September 30, 2025. The filing serves as a vehicle to distribute the company's earnings press release via Exhibit 99.1.
📋 Key Facts
- Reporting date: November 6, 2025
- Period covered: Quarter ended September 30, 2025
- The filing includes a press release as Exhibit 99.1
- The company is classified as an 'emerging growth company'
Entrada Therapeutics, Inc. filed an 8-K to announce its financial results for the quarter ended June 30, 2025. The filing serves as a vehicle to furnish quarterly earnings data and corporate updates via an attached press release.
📋 Key Facts
- Announcement of financial results for the quarter ended June 30, 2025.
- Filing date: August 6, 2025.
- The report includes a press release (Exhibit 99.1) containing corporate updates.
Entrada Therapeutics, Inc. held its 2025 Annual Meeting of Stockholders on June 11, 2025. The meeting resulted in the election of three Class I directors and the ratification of Ernst & Young LLP as the company's independent auditor.
📋 Key Facts
- Annual Meeting held via virtual-only webcast on June 11, 2025.
- Quorum was established with 30,259,526 shares present/represented out of 37,953,417 outstanding.
- Dipal Doshi, Kush M. Parmar, and Mary Thistle were elected to the Board as Class I directors.
- Ernst & Young LLP was ratified as the independent registered public accounting firm for fiscal year ending December 31, 2025.
Entrada Therapeutics expanded its Board of Directors from six to seven members with the appointment of Maha Radhakrishnan, M.D., effective June 1, 2025. Dr. Radhakrishnan will also join the Audit Committee, replacing Kush Parmar, M.D., Ph.D.
📋 Key Facts
- Board size expanded from six to seven directors.
- Maha Radhakrishnan, M.D. appointed as Class III director effective June 1, 2025.
- Dr. Radhakrishnan replaces Kush Parmar, M.D., Ph.D. on the Audit Committee.
- Compensation includes a stock option valued at up to $500,000 or 38,000 shares (vesting over 3 years) and an annual director fee of $40,000 plus $9,000 for Audit Committee service.
- Dr. Radhakrishnan is a former Chief Medical Officer at Biogen, Inc.
Entrada Therapeutics, Inc. announced its financial results for the fiscal quarter ended March 31, 2025. The filing serves as a formal announcement of quarterly earnings and other corporate updates.
📋 Key Facts
- Reporting period: Quarter ended March 31, 2025
- Announcement date: May 8, 2025
- The company is an emerging growth company
- Financial results were released via press release (Exhibit 99.1)
Entrada Therapeutics is implementing a strategic restructuring plan to prioritize its Duchenne muscular dystrophy (DMD) and ocular clinical programs. This includes a workforce reduction of approximately 20% expected to be completed by the end of Q2 2025.
🚩 Red Flags
- Workforce reduction (layoffs) typically indicates a need for cost containment or a shift in capital allocation.
- One-time charges of $2 million incurred primarily in Q2 2025.
📋 Key Facts
- Workforce reduction of approximately 20% effective May 2, 2025.
- Expected one-time charges of approximately $2 million related to severance and healthcare benefits.
- Strategic focus shifted toward DMD clinical candidates (ENTR-601-44, -45, -50, and -51), ocular programs, and platform investments.
- The restructuring is intended to extend the company's cash runway into the second quarter of 2027.
Entrada Therapeutics announced it has received regulatory authorization from the UK's Medicines and Healthcare Products Regulatory Agency to initiate a Phase 1/2 clinical study for its drug candidate ENTR-601-45. The study aims to treat Duchenne Muscular Dystrophy (DMD) in patients amenable to exon 45 skipping.
🚩 Red Flags
- Standard forward-looking statement disclaimer regarding cash runway sufficiency (not specific to this event but noted in text).
📋 Key Facts
- Received authorization from the UK's Medicines and Healthcare Products Regulatory Agency and Research Ethics Committee.
- The clinical trial is a Phase 1/2 multiple ascending dose (MAD) study titled ELEVATE-45-201.
- Target population: Ambulatory patients with Duchenne Muscular Dystrophy (DMD) amenable to exon 45 skipping.
- Primary objectives: Evaluate safety, tolerability, and effectiveness of ENTR-601-45.
- Trial initiation in the United Kingdom is expected in Q3 2025.
Entrada Therapeutics, Inc. announced its financial results for the fiscal quarter ended December 31, 2024, and provided other corporate updates via a press release.
📋 Key Facts
- Reporting period: Quarter ended December 31, 2024
- Announcement date: February 27, 2025
- The filing includes an earnings press release as Exhibit 99.1
- Company is classified as an emerging growth company
Entrada Therapeutics announced that the FDA has lifted a clinical hold on its lead product candidate, ENTR-601-44. This allows for the initiation of a Phase 1b multiple ascending dose clinical study for the treatment of Duchenne muscular dystrophy (DMD).
🚩 Red Flags
- Forward-looking statements include a standard warning regarding the sufficiency of cash resources to fund foreseeable operating expenses.
📋 Key Facts
- FDA has removed the clinical hold on ENTR-601-44.
- The FDA authorized a Phase 1b multiple ascending dose clinical study for DMD in non-ambulatory and ambulatory adult patients.
- The study targets patients with confirmed mutations amenable to exon 44 skipping.
- Company plans to initiate enrollment in the first half of 2026.
- The program includes both U.S. (ELEVATE-44-102) and non-U.S. (ELEVATE-44-201) studies.
Entrada Therapeutics announced regulatory authorization in the United Kingdom to initiate a Phase 1/2 clinical study for its lead product candidate, ENTR-601-44, targeting Duchenne Muscular Dystrophy (DMD). The trial is expected to commence in the second quarter of 2025.
🚩 Red Flags
- Standard forward-looking statement risk regarding cash runway sufficiency (not specific to this event but noted in the disclaimer).
📋 Key Facts
- Received authorization from the UK's Medicines and Healthcarely Products Regulatory Agency (MHRA) and Research Ethics Committee.
- The study, titled ELEVATE-44-201, is a Phase 1/2 multiple ascending dose clinical trial of ENTR-601-44.
- Target population: Patients living with Duchenne Muscular Dystrophy (DMD) with mutations amenable to exon 44 skipping.
- Primary objectives: Evaluate safety, tolerability, and effectiveness in ambulatory patients.
- Timeline: Trial initiation is on track for Q2 2025.
Entrada Therapeutics presented preliminary financial results at the 43rd Annual J.P. Morgan Healthcare Conference, highlighting a strong cash position and extended runway.
🚩 Red Flags
- Information is preliminary and unaudited; actual year-end figures may differ following the ongoing audit.
📋 Key Facts
- Cash, cash equivalents, and marketable securities totaled approximately $420.0 million as of December 31, 2024.
- The company expects current cash resources to fund operations and capital expenditures into the second quarter of 2027.
- Financial results presented are preliminary, unaudited, and subject to change upon completion of the 2024 audit.
Entrada Therapeutics, Inc. announced its financial results for the quarter ended September 30, 2024, and provided other corporate updates via a press release.
📋 Key Facts
- Report date: November 5, 2024
- Reporting period: Quarter ended September 30, 2024
- The filing is an announcement of quarterly financial results and corporate updates under Item 2.02.
- The company is classified as an 'emerging growth company'.
Entrada Therapeutics, Inc. filed an 8-K to furnish its quarterly financial results for the period ending June 30, 2024. The filing serves as a standard announcement of earnings and corporate updates.
📋 Key Facts
- Reported date: August 13, 2024
- Reporting period: Quarter ended June 30, 2024
- The company is classified as an emerging growth company.
- Financial results and corporate updates were released via press release (Exhibit 99.1).
Entrada Therapeutics announced a registered direct offering of approximately $100 million in common stock and pre-funded warrants. The proceeds are intended to fund clinical trials for several pipeline candidates and extend the company's cash runway into 2027.
🚩 Red Flags
- Dilutive offering of significant volume (over 3.3 million shares).
- Pre-funded warrants allow investors to avoid immediate beneficial ownership thresholds, potentially delaying large-scale selling but increasing long-term dilution.
- The company is an 'emerging growth company,' which often correlates with higher burn rates and dependency on capital markets.
📋 Key Facts
- Offering size: Approximately $100 million gross proceeds.
- Securities offered: 3,367,003 shares of common stock at $14.85 per share and an equivalent number of pre-funded warrants at $14.8499 per warrant.
- Use of proceeds: Funding Phase 2b trials for ENTR-601-44 and ENTR-601-45, a Phase 2 MAD trial for ENTR-601-50, R&D pipeline development, and working capital.
- Cash runway extension: Management expects proceeds to extend cash runway into 2027.
- Registration rights: Entered into an Affiliate Registration Rights Agreement with Baker Funds (Baker Brothers Life Sciences, L.P. and 667, L.P.).
- Restrictive covenants: The company is prohibited from issuing convertible securities or effecting a reverse stock split for 30 days following the closing.
Entrada Therapeutics announced positive preliminary Phase 1 clinical trial data for its lead product candidate, ENTR-601-44, targeting Duchenne muscular dystrophy (DMD). The data demonstrated favorable safety and dose-dependent target engagement via exon skipping.
🚩 Red Flags
- Clinical stage company; results are preliminary and subject to regulatory feedback.
- Forward-looking statements include risks regarding cash runway sufficiency (standard for biotech).
📋 Key Facts
- Phase 1 trial evaluated safety, tolerability, pharmacokinetics, and target engagement of ENTR-601-44 in 32 healthy male volunteers.
- No serious adverse events (SAEs) or drug-related adverse events were reported; all TEAEs were mild or moderate.
- Target engagement (exon skipping) was statistically significant in Cohort 4 compared to placebo (p<0.005).
- Mean exon skipping in Cohort 4 was 0.43% ± 0.14% vs. 0.29% in Cohort 3 and 0.22% in placebo.
- Company plans to submit regulatory applications in Q4 2024 for Phase 2 trials of ENTR-601-44 and ENTR-601-45.
Entrada Therapeutics held its 2024 Annual Meeting of Stockholders on June 13, 2024. Shareholders approved the election of a new director, ratified the appointment of Ernst & Young LLP as independent auditors, and approved an amendment to limit the liability of certain officers.
🚩 Red Flags
- None identified in this filing.
📋 Key Facts
- Annual Meeting held virtually via live webcast on June 13, 2024.
- Gina Chapman was elected to the Board as a Class III director (received 19,701,297 votes 'for').
- Ratification of Ernst & Young LLP as independent registered public accounting firm for fiscal year ending Dec 31, 2024.
- Approval of Certificate of Amendment to limit the liability of certain officers under Delaware law.
- Quorum was established with 22,221,263 shares present/represented out of 33,677,918 outstanding.
Entrada Therapeutics, Inc. filed an 8-K to announce its financial results for the quarterly period ended March 31, 2024. The filing serves as a formal mechanism to furnish the company's earnings press release.
📋 Key Facts
- Reporting date: May 7, 2024
- Period covered: Quarter ended March 31, 2024
- The report includes an announcement of financial results and other corporate updates via Exhibit 99.1.
- The company is classified as an 'emerging growth company'.
Entrada Therapeutics, Inc. filed an 8-K to furnish its year-end financial results for the fiscal year ended December 31, 2023, along with other corporate updates via a press release.
📋 Key Facts
- Report date: March 13, 2024
- Reporting period: Year ended December 31, 2023
- The filing is intended to furnish financial results and corporate updates rather than being 'filed' for liability purposes under Section 18.
- Company is classified as an emerging growth company.
Entrada Therapeutics, Inc. announced a leadership restructuring where Nathan J. Dowden is promoted to President (effective Jan 1, 2024) while retaining his COO role. Dipal Doshi will remain as CEO.
🚩 Red Flags
- None identified; the filing describes a promotion/restructuring rather than an exit or departure of key personnel.
📋 Key Facts
- Nathan J. Dowden appointed as President effective January 1, 2024.
- Mr. Dowden will continue to serve in his existing role as Chief Operating Officer (COO).
- Dipal Doshi remains the Company's Chief Executive Officer (CEO).
- Mr. Dowden's annual salary increased to $480,000 with a 45% target bonus.
- Grant of 60,000 restricted stock units (RSUs) vesting over three years starting March 1, 2024.